Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutationsHanako Hasegawa, Kenzo Soejima, Hiroyuki Yasuda et al.|Lung Cancer|2018Cited by 50
Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung CancerKota Ishioka, Koichi Fukunaga, Keiko Ohgino et al.|Cancer Research|2021Cited by 43
Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with CetuximabAyano Oashi, Kenzo Soejima, Hiroyuki Yasuda et al.|Molecular Cancer Therapeutics|2019Cited by 4
Table S1-S5, Figure S1-S12 from Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung CancerKota Ishioka, Koichi Fukunaga, Hiroyuki Yasuda et al.|Unknown|2023Cited by 0
Supplementary Figures S1-S11 from Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with CetuximabAyano Oashi, Kenzo Soejima, Hiroyuki Yasuda et al.|Unknown|2023Cited by 0